ASTRO 2022 | Rationale and study design of Phase II trial comparing TACE and SBRT for hepatocellular carcinoma

Alejandra Mendez Romero, MD, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the rationale and study design of a randomized Phase II multicenter study (NCT02470533) which compared the use of transarterial chemoembolization with drug-eluting beads to the use of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC). The target enrollment of the study was 100 patients, with the primary endpoint being time to progression.

This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.